The Company has a global license agreement for the acute pulmonary that could pay up to $78.9 million in development, regulatory and commercial ...

This biotech-focused fund made a big bet on Liquidia just as the company's YUTREPIA drug notched its first full quarter of ...

Background Bronchoscopic limitations in reaching peripheral pulmonary lesions (PPLs) can compromise biopsy sensitivity, ...

Mid Yorkshire Teaching NHS Trust has become the first site in Europe to recruit a patient to a major international clinical ...

Merck & Co., Inc. acquires Cidara Therapeutics, Inc. for $9.2bn, boosting its pipeline with CD388's strong flu data. Click ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, Nov. 17th: Roku ROKU ...

The article " Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything " first appeared on MarketBeat.

A Scotland-based drug delivery device developer has secured an additional £1.5 million in seed funding to drive development ...

Discover key Q3 2025 insights from Achieve Life Sciences as they expedite cytisinicline’s FDA approval for nicotine dependence.

The Cornwall and Isles of Scilly Commercial Research Delivery Centre (CIOS CRDC) said it was selected as a delivery site for a clinical trial of a new type of vaccine designed to prevent or reduce the ...

Merck's $9.2 billion proposed Cidara acquisition will add CD388 to the pipeline, boosting the respiratory portfolio and ...

Merck & Co. has agreed to acquire Cidara Therapeutics for approximately $9.2 billion, the companies said, in a deal designed to bolster the buyer’s antiviral portfolio with a Phase III drug designed ...